Timothy G. Daly serves as Executive Vice President - Finance, Corporate Controller, Treasurer of the Company. Mr. Daly previously served as Senior Vice President, Finance and Corporate Controller and as Vice President, Finance and Corporate Controller from January 2018 to November 2019 and September 2015 to January 2018, respectively. Prior to joining us, Mr. Daly was Vice President of Finance and Corporate Controller at Advanced Health Media LLC, a global provider of technology to healthcare professionals, from 2013 to September 2015. Previously, he served as Vice President, Controller and Chief Accounting Officer at Enzon Pharmaceuticals, Inc., a publicly held pharmaceutical company, from 2011 to 2013. Before that, Mr. Daly served in various operational finance roles at ImClone Systems Incorporated from 1999 to 2011, including during the commercial launch of Erbitux®, and most recently as Director of Finance. Mr. Daly earned his B.S. in accounting from Rider University.
As the Executive Vice President - Finance, Corporate Controller et Treasurer of Ovid Therapeutics Inc, the total compensation of Timothy Daly at Ovid Therapeutics Inc is $897,279. There are 3 executives at Ovid Therapeutics Inc getting paid more, with Jeremy Levin having the highest compensation of $3,008,980.
Timothy Daly is 48, he's been the Executive Vice President - Finance, Corporate Controller et Treasurer of Ovid Therapeutics Inc since 2019. There are 14 older and 2 younger executives at Ovid Therapeutics Inc. The oldest executive at Ovid Therapeutics Inc is Bart Friedman, 75, who is the Lead Independent Director.
Timothy's mailing address filed with the SEC is C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK, NY, 10036.
Over the last 8 years, insiders at Ovid Therapeutics Inc have traded over $37,290 worth of Ovid Therapeutics Inc stock and bought 2,202,070 units worth $5,624,523 . The most active insiders traders include Pharmaceutical Co Ltdmillen..., Barbara Gayle Duncan et Jeremy M Levin. On average, Ovid Therapeutics Inc executives and independent directors trade stock every 218 days with the average trade being worth of $229,440. The most recent stock trade was executed by Jeremy M Levin on 18 March 2024, trading 18,248 units of OVID stock currently worth $50,364.
ovid therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. ovid’s drug candidate, ov101, is currently in development for the treatment of symptoms of angelman syndrome and fragile x syndrome. ovid is also developing ov935 in collaboration with takeda pharmaceutical company limited for the treatment of rare epileptic encephalopathies. ovid has initiated the phase 2 stars trial of ov101 in adults with angelman syndrome and a phase 1 trial in adolescents with angelman and fragile x syndrome to identify doses suitable for younger patients. review our community guidelines: http://www.ovidrx.com/community-guidelines/
Ovid Therapeutics Inc executives and other stock owners filed with the SEC include: